Rifamycin

CHEMBL437765 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

697.8 g/mol

LogP

4.9

Phase

4

Rifamycin is a macrocyclic antibiotic of the ansamycin class produced by Amycolatopsis rifamycinica that inhibits bacterial DNA-dependent RNA polymerase by binding to its beta subunit, blocking transcription initiation and RNA chain elongation in susceptible bacteria. It is used as a non-absorbable oral antibiotic for prevention of traveler's diarrhea and treatment of hepatic encephalopathy, and is also the parent compound of the clinically important rifamycin derivatives.

Molekularmasse

697,8000 g/mol

LogP

4,90

TPSA

201,00 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Oncology Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C

InChI

InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1

Molecular Formula

C37H47NO12

HBD / HBA

6 / 12

Rotierbare Bindungen

3

Schwere Atome

50

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Rifamycin is a macrocyclic antibiotic of the ansamycin class produced by Amycolatopsis rifamycinica that inhibits bacterial DNA-dependent RNA polymerase by binding to its beta subunit, blocking transcription initiation and RNA chain elongation in susceptible bacteria. It is used as a non-absorbable oral antibiotic for prevention of traveler's diarrhea and treatment of hepatic encephalopathy, and is also the parent compound of the clinically important rifamycin derivatives.

Yes, Rifamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL437765. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6324616. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Rifamycin auf PillFYI

Struktur

Schnelldaten

Formel: C37H47NO12

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.